Form 4: Zymeworks Director Neil Gallagher Acquires 74,000 Stock Options

Director Neil Gallagher acquired 74,000 stock options in Zymeworks Inc. on April 2, 2024.

Summary

• On April 2, 2024, Neil Gallagher, a director of Zymeworks Inc., acquired 74,000 stock options.
• The exercise price of these options is $9.23.
• The options vest in 36 equal monthly installments starting one month after the grant date.
• The expiration date for these options is April 1, 2034.
• Following the transaction, Gallagher directly owns 74,000 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of a stock option grant to a director. While insider ownership is generally viewed positively, this specific event is more procedural.

Positives

• A director's acquisition of stock options can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders. This filing indicates a director's activity in acquiring stock options, which is a common form of executive compensation in the biotechnology industry.

Comparison to Industry Standards

• Stock option grants are a typical component of compensation packages for directors and executives in biotech companies like Zymeworks.
• Comparing the vesting schedule (36 months) and exercise price ($9.23) to similar grants at comparable companies (e.g., Seagen, BioNTech) would provide context on the competitiveness of Zymeworks' compensation practices.
• The ten-year expiration date is also standard practice.

Stakeholder Impact

• The acquisition of stock options by a director could have a minor positive impact on shareholder sentiment, as it aligns the director's interests with those of the shareholders.

Key Dates